Sorrento Therapeutics (LTS:0L85) 3-Year Revenue Growth Rate : -12.50% (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics 3-Year Revenue Growth Rate?

Sorrento Therapeutics's Revenue per Share for the three months ended in Jun. 2023 was $0.03.

During the past 12 months, Sorrento Therapeutics's average Revenue per Share Growth Rate was -22.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -12.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was -32.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Sorrento Therapeutics was 147.10% per year. The lowest was -56.80% per year. And the median was 14.35% per year.

Competitive Comparison of Sorrento Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Sorrento Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sorrento Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's 3-Year Revenue Growth Rate falls into.

Sorrento Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Sorrento Therapeutics (LTS:0L85) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Sorrento Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sorrento Therapeutics (LTS:0L85) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

SRNEQ:USA

Address

4955 Directors Place, San Diego, CA, USA, 92121

Website

https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines